Seattle Genetics, Genmab turn on TV for a highlight reel in cervical cancer — but a rival biotech promises a better show

John Carroll

Editor & Founder

Seattle Genetics $SGEN and their partners at Genmab $GMAB polished up some positive Phase II numbers for their antibody drug conjugate tisotumab vedotin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Seattle Genetics, Genmab turn on TV for a highlight reel in cervical cancer — but a rival biotech promises a better show

John Carroll

Editor & Founder

Sign up to read this article for free.

Intellia to cut workforce by 27%, plans commercialization of first CRISPR therapy in 2027

Lilly ventures into pulmonary fibrosis with startup Mediar

John Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet; Amylyx names commercial chief

With $120M, GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring

Another biotech scoops up asset from China-based Keymed and nabs $180M

Repare pauses late-stage plans, reshuffles pipeline in effort to cut costs

Seat­tle Ge­net­ics, Gen­mab turn on TV for a high­light reel in cer­vi­cal can­cer — but a ri­val biotech promis­es a bet­ter show

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

In­tel­lia to cut work­force by 27%, plans com­mer­cial­iza­tion of first CRISPR ther­a­py in 2027

Lil­ly ven­tures in­to pul­monary fi­bro­sis with start­up Me­di­ar

John Maraganore turns to ex-Al­ny­lam col­league to lead his lat­est RNAi bet; Amy­lyx names com­mer­cial chief

With $120M, GSK-al­lied Ouro Med­i­cines throws its hat in­to bur­geon­ing TCE ring

An­oth­er biotech scoops up as­set from Chi­na-based Keymed and nabs $180M

Re­pare paus­es late-stage plans, reshuf­fles pipeline in ef­fort to cut costs

Seattle Genetics, Genmab turn on TV for a highlight reel in cervical cancer — but a rival biotech promises a better show

Intellia to cut workforce by 27%, plans commercialization of first CRISPR therapy in 2027

Lilly ventures into pulmonary fibrosis with startup Mediar

John Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet; Amylyx names commercial chief

With $120M, GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring

Another biotech scoops up asset from China-based Keymed and nabs $180M

Repare pauses late-stage plans, reshuffles pipeline in effort to cut costs